{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-110103","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.014673+00:00","generated_at":"2026-06-23T02:20:54.841831+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"HOOKIPA signs collaboration with Roche for KRAS-mutated cancer therapy; $25M upfront, up to $930M milestones","bullets":["HOOKIPA receives $25 million upfront; eligible for up to ~$930 million in total milestone payments plus tiered royalties.","Roche licenses HB-700, an arenaviral immunotherapy for KRAS-mutated cancers; HOOKIPA conducts research through Phase 1b.","Roche obtains an exclusive option to license a second undisclosed arenaviral immunotherapy for an additional $15 million payment.","Tiered royalties of high single-digit to mid-teens percent on worldwide net sales for both programs upon commercialization.","First oncology licensing collaboration for HOOKIPA; partnership validates its arenavirus platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-110103","json":"https://secwatch.observer/filing/0001104659-22-110103.json","markdown":"https://secwatch.observer/filing/0001104659-22-110103.md","text":"https://secwatch.observer/filing/0001104659-22-110103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922110103/0001104659-22-110103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465922110103/tm2228531d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:20:54.841831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}